Enanta Pharmaceuticals Inc

9EP

Company Profile

  • Business description

    Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

  • Contact

    4 Kingsbury Avenue
    WatertownMA02472
    USA

    T: +1 617 607-0800

    E: [email protected]

    https://www.enanta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2026

    Employees

    120

Stocks News & Analysis

stocks

Production increase on track for ASX hydrocarbon producer

Our view after lower earnings.
stocks

Market pricing in further upside in overvalued ASX bank

We view the shares are materially overvalued.
stocks

Chart of the Week: Lithium is rebounding on rising demand

The mining sector is significantly overvalued on average but select value to be found.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,316.6023.80-0.25%
CAC 408,429.030.000.00%
DAX 4025,278.21279.811.12%
Dow JONES (US)49,662.66129.470.26%
FTSE 10010,686.18130.011.23%
HKSE26,705.94138.820.52%
NASDAQ22,753.63175.250.78%
Nikkei 22557,468.89325.050.57%
NZX 50 Index13,444.20197.181.49%
S&P 5006,881.3138.090.56%
S&P/ASX 2009,086.2024.30-0.27%
SSE Composite Index4,082.0751.95-1.26%

Market Movers